Richard I Steinhart sold $207 of BTAIQ
Chief Financial Officer at BioXcel Therapeutics, Inc.. 577 shares at an average of $0.36, traded Dec 16, 2024, filed Dec 17, 2024.
Score components
- +22RoleCFO
- 0Trade size$207 at market
- 0Share of holdings soldSold 2.7% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-24-129461, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 14, 2024 | MOption exercise Common Stock10b5-1 | +521 | - | - | 20,800 | Dec 17, 2024 |
| Dec 15, 2024 | MOption exercise Common Stock10b5-1 | +562 | - | - | 21,362 | Dec 17, 2024 |
| Dec 16, 2024 | SOpen-market sale Common Stock10b5-1 | -205 | $0.36 | $74 | 21,157 | Dec 17, 2024 |
| Dec 16, 2024 | SOpen-market sale Common Stock10b5-1 | -372 | $0.36 | $133 | 20,932 | Dec 17, 2024 |
| Dec 14, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -521 | $0.00 | $0 | 2,606 | Dec 17, 2024 |
| Dec 15, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -562 | $0.00 | $0 | 5,064 | Dec 17, 2024 |
Related signals
Other insiders at BioXcel Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | BioXcel Therapeutics, Inc. | Vimal Mehta CEO and President | $21k 19,419 shares | -22% | |
| 7Weak | BioXcel Therapeutics, Inc. | Richard I Steinhart Chief Financial Officer | $7,427 6,845 shares | -21% | |
| 0Weak | BioXcel Therapeutics, Inc. | Javier Rodriguez See Remarks | $7,111 6,560 shares | -20% | |
| 0Weak | BioXcel Therapeutics, Inc. | Frank Yocca Chief Scientific Officer | $7,427 6,845 shares | -21% | |
| 0Weak | BioXcel Therapeutics, Inc. | Frank Yocca Chief Scientific Officer | $152 430 shares | -1% | |
| 0Weak | BioXcel Therapeutics, Inc. | Javier Rodriguez See Remarks | $153 430 shares | -2% | |
| 5Weak | BioXcel Therapeutics, Inc. | Vimal Mehta CEO and President | $1,131 3,117 shares | -5% | |
| 0Weak | BioXcel Therapeutics, Inc. | Vincent O'Neill See Remarks | $58 165 shares | -1% | |
| 0Weak | BioXcel Therapeutics, Inc. | Matthew T. Wiley Chief Commercial Officer | $149 215 shares | -5% | |
| 0Weak | BioXcel Therapeutics, Inc. | Vincent O'Neill See Remarks | $95 138 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.